Basilea Pharmaceutica Ltd. Logo
 
Search
 

News

 
 
Language
Year
Keyword
 
Wednesday, January 10. 2018
 
Basel, Switzerland, January 10, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today the completion of its extension of its license agreement with Pfizer Inc. (NYSE: PFE) for Basilea's antifungal Cresemba® (isavuconazole) to include China (with Hong Kong and Macao) and sixteen countries in the Asia Pacific region, execution of which was announced on December 1, 2017. The amendment was subject to customary regulatory review which has completed. Isavuconazole is an antifungal for the treatment of life-threatening invasive mold infections.
 
more...
 
Wednesday, January 03. 2018
 
Basel, Switzerland, January 03, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the initiation of a phase 1 study conducted under its clinical study agreement with the Adult Brain Tumor Consortium (ABTC) in the U.S. The first patient has been treated in this open-label dose-escalation study to determine the safety and tolerability of the oral formulation of Basilea's novel anticancer drug candidate BAL101553 in combination with standard radiation in patients with newly-diagnosed glioblastoma. Patients participating in the study have a reduced sensitivity to standard chemotherapy with temozolomide due to an unmethylated MGMT promoter.
 
more...
 
Thursday, December 21. 2017
 
Basel, Switzerland, December 21, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated its investigational drug ceftobiprole as a Qualified Infectious Disease Product (QIDP). The designation relates to the potential use of the drug in the treatment of bacterial bloodstream infections (bacteremia) caused by Staphylococcus aureus.
 
more...
 
Friday, December 01. 2017
 
  • Basilea eligible to receive additional upfront and milestone payments of up to USD 226 million and mid-teen royalties on sales
  • Basilea updates its financial guidance for 2017 - improved result expected
 
more...
 
Thursday, November 02. 2017
 
  • Cresemba launched by Pfizer in Spain and is now commercially available in all Top-5 EU markets
  • Marketing authorization received for Switzerland
 
more...
 
Tuesday, October 31. 2017
 
Basel, Switzerland, October 31, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Prof. Achim Kaufhold will retire after seven years with the company. Basilea named Dr. Marc Engelhardt, currently Basilea's Head of Development, to succeed Prof. Kaufhold in the role of Chief Medical Officer and as a member of the Management Committee effective January 1, 2018.
 
more...
 
Monday, October 23. 2017
 
Basel, Switzerland, October 23, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) in the United States exceeded the threshold triggering the first sales milestone payment from Astellas Pharma Inc. ("Astellas") to Basilea in the amount of CHF 5 million.
 
more...
 
Thursday, September 28. 2017
 
Basel, Switzerland, September 28, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun) for Basilea's antibiotic Zevtera® (ceftobiprole) in China, Hong Kong and Macao (the Territory).
 
more...
 
Tuesday, September 12. 2017
 
Basel, Switzerland, September 12, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a distribution agreement with Cardiome Pharma Corp. (Cardiome; NASDAQ: CRME, TSX: COM) for Basilea's antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe (excluding Nordic countries) and Israel.
 
more...
 
Thursday, August 10. 2017
 
  • Completed license agreement with Pfizer for Cresemba in Europe (excluding Nordics), Russia, Turkey and Israel; CHF 70 million upfront payment and up to USD 427 million in milestones
  • 56 percent increase in total revenue, amounting to CHF 46.2 million
  • BARDA committed USD 54.8 million in additional funding to support phase 3 development of ceftobiprole for registration in the U.S.
  • Agreement with Adult Brain Tumor Consortium for phase 1 clinical study to explore BAL101553 in newly diagnosed glioblastoma
 
more...
 
more
Info